OncoDNA
Company specialized in precision medicine for the treatment of cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
* | N/A | $7.1m Valuation: $103m -20.8x EV/EBITDA | Series C |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
OncoDNA, established in 2012 by Jean-Pol Detiffe and Jean-Claude Havaux, operates at the intersection of genomics and oncology, providing advanced molecular profiling solutions. Detiffe, with a background in molecular biology and experience at a diagnostics company, co-founded the firm to translate genomic data into actionable clinical insights for cancer treatment. The company's core business revolves around precision medicine, offering a suite of services that analyze the molecular complexity of tumors to guide therapeutic decisions.
The company serves a diverse client base, including clinicians, academic researchers, and biopharmaceutical companies, assisting them in navigating the complexities of cancer treatment and drug development. OncoDNA's business model is multifaceted, generating revenue through its comprehensive portfolio which includes Next-Generation Sequencing (NGS) services, biomarker testing, and the licensing of its data interpretation software and clinical decision support tools. This integrated approach allows the company to support the entire oncology ecosystem, from patient diagnosis and monitoring to facilitating clinical trials and pharmaceutical research.
OncoDNA's key offering is a portfolio of solutions that combine various analyses. OncoDEEP provides a comprehensive genomic and proteomic analysis from a tumor tissue sample to guide treatment for solid cancers. For monitoring treatment efficacy and detecting relapse, OncoSELECT is a liquid biopsy solution that analyzes circulating tumor DNA. Additionally, the company provides OncoSTRAT&GO, which combines both tissue and liquid biopsy analyses for a complete patient molecular profile. These services are powered by the OncoKDM platform, a proprietary software that translates complex data into clear clinical recommendations, enabling personalized treatment strategies.
Keywords: precision oncology, genomic profiling, theranostics, biomarker testing, liquid biopsy, clinical decision support, NGS services, cancer diagnostics, molecular diagnostics, data interpretation software